A phase 2 liver trial where the add-on drug didn't help — and the base drug quietly did
Read the Sunday Brief →

Study wrapper · #33

BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1.

Zhang J, Liu M, Ou H, et al. Cell communication and signaling : CCS. 2026.
Weak / noneIn vitroMentions: BPC-157

Editor's note

This in-vitro study proposes a specific molecular mechanism for BPC-157's well-documented proangiogenic effects — a mechanistic gap that has long complicated its translational narrative. Researchers report that BPC-157 interacts with the E3 ubiquitin ligase adaptor FBXO22 via its third-position proline residue, forming a complex that blocks the proteasomal degradation of the transcription factor BACH1. The resulting BACH1 accumulation was associated with increased proliferation and tube-forming capacity in vascular endothelial cells.

The finding is mechanistically specific and, if reproducible, would constitute a genuinely novel axis — BPC157-FBXO22-BACH1 — distinct from the NO-system and growth-hormone-receptor pathways previously proposed. That specificity is worth noting.

However, this is a cell and tissue study. These are preclinical, mechanistic signals; human data are needed before clinical conclusions can be drawn. In-vitro tube-forming assays and proliferation metrics are several steps removed from physiologically meaningful angiogenesis in a living system. The study does not report adverse events, as none are applicable in this model.

Given that BPC-157's broader...

Plain-language abstract

This laboratory study investigated how BPC-157 — a synthetic peptide of 15 amino acids — promotes the growth of new blood vessels, a process called angiogenesis. Researchers used molecular and biochemical techniques in cell and tissue experiments to trace the specific biological pathway involved.

The study found that BPC-157 enters cells and interacts with a protein called FBXO22, which normally helps tag other proteins for destruction by the cell's disposal machinery. This interaction — dependent on a specific proline amino acid at the third position of BPC-157's structure — blocks FBXO22 from marking a transcription factor called BACH1 for breakdown. As a result, BACH1 accumulates inside the cell at higher-than-normal levels.

Researchers showed that this build-up of BACH1 was associated with two processes important for forming new blood vessels: increased multiplication of vascular endothelial cells (the cells that line blood vessels) and an improved ability of those cells to organize into tube-like structures resembling blood vessels.

The study concludes that a BPC-157–FBXO22–BACH1 pathway represents a previously unrecognized mechanism behind BPC-157's vascular effects, and suggests it could inform future research into blood-vessel repair therapies.

These are preclinical findings from cell-based experiments; human data are needed before any clinical conclusions can be drawn. No adverse events were reported, as none are applicable in this type of laboratory model.